Trials / Unknown
UnknownNCT04708210
Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors
An Open-label, Multicenter, Phase Ia/Ib Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of IBI319 in Patients With Advanced Malignant Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 256 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, multicenter, phase Ia/Ib study to evaluate the safety, tolerance and preliminary efficacy of IBI319 in patients with advanced malignant tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI319 | Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit. |
Timeline
- Start date
- 2021-04-28
- Primary completion
- 2022-12-21
- Completion
- 2023-06-21
- First posted
- 2021-01-13
- Last updated
- 2022-10-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04708210. Inclusion in this directory is not an endorsement.